Crosstalk between epigenetic therapy and anti-tumor immunity in the treatment of hematopoietic neoplasms
| Project/Area Number |
16K15499
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Goyama Susumu 東京大学, 医科学研究所, 准教授 (80431849)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
北村 俊雄 東京大学, 医科学研究所, 教授 (20282527)
|
|---|
| Research Collaborator |
Hayashi Yasutaka
Saika Makoto
Yonezawa Taishi
Liu XiaoXiao
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 腫瘍免疫 / エピジェネティクス / p53 / DNAメチル化阻害剤 / ヒストンアセチル化阻害剤 / 急性骨髄性白血病 / 骨髄異形成症候群 / ヒストン脱アセチル化阻害剤 / MLL転座型白血病 / 免疫不全マウス / 造血器腫瘍 |
|---|
| Outline of Final Research Achievements |
“Epigenetic therapy” and “tumor immunotherapy” have attracted considerable attention in recent years as new therapeutic strategies against tumors. However, how these therapies show anti-tumor effect is not fully understood. In this study, we transplanted murine blood tumors into both immunocompetent C57BL/6 mice and immunodeficient NSG mice, and treated these mice with a variety of drugs. We found that a DNA methylation inhibitor and a p53-activating drug suppressed leukemia progression with the assistance of tumor immunity. Furthermore, we showed the anti-tumor effect of an HDAC inhibitor using a mouse model for myelodysplastic syndrome. These findings will be the basis of future development of new epigenetic therapies and tumor immunotherapies for hematopoietic neoplasms.
|
Report
(3 results)
Research Products
(7 results)
